- Home
- SAVA vs GGT Comparison
SAVA vs GGT Comparison
Compare SAVA & GGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- GGT
- Stock Information
- Founded
- SAVA 1998
- GGT 1994
- Country
- SAVA United States
- GGT United States
- Employees
- SAVA N/A
- GGT N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- GGT Trusts Except Educational Religious and Charitable
- Sector
- SAVA Health Care
- GGT Finance
- Exchange
- SAVA Nasdaq
- GGT Nasdaq
- Market Cap
- SAVA 137.2M
- GGT N/A
- IPO Year
- SAVA N/A
- GGT N/A
- Fundamental
- Price
- SAVA $1.38
- GGT $4.64
- Analyst Decision
- SAVA Buy
- GGT
- Analyst Count
- SAVA 3
- GGT 0
- Target Price
- SAVA $54.50
- GGT N/A
- AVG Volume (30 Days)
- SAVA 2.2M
- GGT 59.7K
- Earning Date
- SAVA 05-09-2025
- GGT 01-01-0001
- Dividend Yield
- SAVA N/A
- GGT 15.56%
- EPS Growth
- SAVA N/A
- GGT N/A
- EPS
- SAVA N/A
- GGT 0.83
- Revenue
- SAVA N/A
- GGT N/A
- Revenue This Year
- SAVA N/A
- GGT N/A
- Revenue Next Year
- SAVA N/A
- GGT N/A
- P/E Ratio
- SAVA N/A
- GGT $6.90
- Revenue Growth
- SAVA N/A
- GGT N/A
- 52 Week Low
- SAVA $1.35
- GGT $4.32
- 52 Week High
- SAVA $42.20
- GGT $7.00
- Technical
- Relative Strength Index (RSI)
- SAVA 23.37
- GGT 37.80
- Support Level
- SAVA $1.63
- GGT $4.56
- Resistance Level
- SAVA $1.79
- GGT $4.94
- Average True Range (ATR)
- SAVA 0.19
- GGT 0.10
- MACD
- SAVA -0.14
- GGT -0.01
- Stochastic Oscillator
- SAVA 1.76
- GGT 21.05
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.